Insys Therapeutics Inc (INSYQ)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

10220 SOUTH 51ST STREET PHOENIX, AZ 85044

NeoPharm is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of cancer. Co. has built a drug portfolio based on its two proprietary technology platforms: the NeoLipid? liposomal drug delivery system, and a tumor-targeting toxin platform. As of Dec 31 2006, Co. had four drug product candidates in various stages of clinical development for the treatment of cancer. Co.'s core drug product candidate is CINTREDEKIN BESUDOTOX, a tumor-targeting toxin being developed as a treatment for glioblastoma multiforme, which is a form of brain cancer. Insys Therapeutics, Inc., based in Phoenix, Arizona, is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. It seeks to apply new and proprietary formulations and delivery methods to existing pharmaceutical compounds in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Its drug development program is based on existing compounds with known safety, efficacy and commercialization histories.

Data as of 2020-04-02
Market Cap3.132 Million Shares Outstanding74.569 Million Avg 30-day Volume16.182 Thousand
P/E Ratio Dividend Yield EPS-3.06
Price/Sales Price cash flow ratio Price free cash flow ratio
Book Value-2.2 Price to Tangible Book-0.14 Alpha-0.07
Short Interest Ratio5.7 % Short Interest to Float13.9 R-squared0.05781
BETA1.9221 52-week High/Low4.97 / 0.024 Stddev0.286602
View SEC Filings from INSYQ instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) 0 (0.0%)
13F shares: 1 1 0.0% 0
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls 0
Total Puts 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding INSYQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INSYQ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LONG ANDREW G CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
62,075 2019-04-17 0

HOUSLEY ANDRECE CHIEF FINANCIAL OFFICER

  • Officer
20,994 2019-04-17 0

MAHBOOB VASEEM

  • Director
14,083 2019-03-04 0

BOHLEN ELIZABETH

  • Director
14,083 2019-03-04 0

NANCE MARK E CHIEF LEGAL OFFICER & GEN CNSL

  • Officer
25,000 2019-01-25 0

VISHNOI ROHIT

  • Director
10,000 2018-05-08 0

MOTAHARI SAEED PRESIDENT & CEO

  • Officer
  • Director
26,400 2018-04-17 0

VANHOVE GEERTRUI

  • Director
0 2018-04-02 0

MEYER STEVEN J

  • Director
68,166 2018-03-05 0

LAPALME PIERRE

  • Director
19,083 2018-03-05 0

JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989

KAPOOR JOHN N

  • 10% Owner
42,536,080 2018-02-27 0

INSYS THERAPEUTICS, INC. VOTING TRUST

  • 10% Owner
0 2018-02-27 0

TAMBI BRIAN

  • Director
0 2018-02-21 0

DEL FOSSE FRANC GENERAL COUNSEL

  • Officer
0 2017-11-17 0

FOURTEAU PATRICK

  • Director
69,682 2017-08-04 0

STANLEY THEODORE H

  • Director
0 2017-02-21 0

KAPOOR JOHN N

  • Director
  • 10% Owner
0 2017-02-21 0

BAKER DARRYL S CHIEF FINANCIAL OFFICER

  • Officer
0 2017-02-21 0

VETTICADEN SANTOSH INTERIM CEO AND CMO

  • Officer
0 2017-02-21 0

BRENNAN DANIEL EXEC VP & CHF OPERATIONS OFF.

  • Officer
1 2016-08-09 0

BABICH MICHAEL L PRESIDENT AND CEO

  • Officer
  • Director
421,572 2015-09-22 0

HOMRICH CHRISTOPHER F SR. VP OPERATIONS

  • Officer
0 2014-08-07 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments